For decades, millions of women navigated a diagnosis that its own name described poorly. Polycystic Ovary Syndrome — PCOS — pointed to ovarian cysts as the defining feature of a condition that is, in reality, far more complex. On Tuesday, that changed.
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new official name for the condition previously known as Polycystic Ovary Syndrome (PCOS), which affects 1 in 8, or more than 170 million women worldwide. The rename was published yesterday in The Lancet and simultaneously announced at the European Congress of Endocrinology in Prague.
What may appear to be an unremarkable one-letter change in nomenclature follows more than a decade of vigorous debate over the need for a name that more precisely and completely describes the condition.
The core problem with the old name was that it was, in a clinical sense, wrong — and that wrongness had real consequences for patients.
The term PCOS was inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing.
PMOS is characterized by fluctuations in hormones, with wide-ranging impacts on weight, metabolic and mental health, skin, and the reproductive system. Despite having hormone dysregulation, insulin resistance, and metabolic disruption at its core, none of these hallmarks were captured by the old name's fixation on ovaries and cysts.
The new name recognizes that the condition is not a primarily gynecological disorder, but is instead a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological, and psychological health.
Giving additional credence to the name change, a companion paper published alongside the renaming study confirmed that the cysts implied by the former name do not even characterize the condition accurately. Researchers found there is no increase in abnormal ovarian cysts among PMOS patients, further demonstrating the need to change the name.
The new name did not emerge quickly or easily. The name change journey took 14 years of global collaboration between experts and those with lived experience.
Leading the effort was Professor Helena Teede, Director of the Monash Centre for Health Research and Implementation at Monash University in Australia and an endocrinologist at Monash Health. But she wasn’t alone: The renaming process involved collaboration across 56 academic, clinical, and patient organizations, as well as multiple global surveys that got responses from over 14,300 patients and practitioners.
According to a press release from the Endocrine Society, when including additional consultation rounds, “resulted in more than 22,000 survey responses and involved multiple international workshops with patients and multidisciplinary health professionals.”
Researchers identified guiding principles that prioritized scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and implementation feasibility.
In a statement, Professor Teede described the change as the largest initiative of its kind ever undertaken for a medical condition. "The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation," she said. "This change was driven with and for those affected by the condition and we are proud to have arrived at a new name that finally accurately reflects the complexity of the condition."
One of the more delicate challenges the renaming process faced was ensuring the new terminology would be appropriate and sensitive across vastly different cultural contexts.
Weighing the word "ovarian" proved trickier, but it was ultimately chosen because other terms, such as "reproductive," were seen as more stigmatizing. In many cultures, unfortunately the worth or value of a woman is often seen to be linked to her fertility.
For people living with the condition, the name change represents more than semantics. Lorna Berry, an Australian woman with PMOS who was involved in the renaming process, framed the stakes in personal terms. "This is about accountability and progress," she said. "It is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning."
The change is expected to ripple through clinical practice, medical education, and research funding. The recategorizing will include updates to clinical guidelines, medical education, and international disease classification systems, ensuring the new terminology is adopted consistently worldwide.
A three-year transition period is beginning now, with the new name to be implemented into an International Guideline update due in 2028.
A suite of additional academic papers by the same experts are being published on the need for and implications of the name change on a variety of issues including adolescent health, maternal health, clinical practice, policy reform and research.
For Professor Teede, who has spent her career researching the condition and witnessing its costs firsthand, the renaming is the culmination of work that was always as much about justice as science.
The announcement arrives at a moment of growing recognition that women's health conditions have long been under-researched, under-diagnosed, and inadequately named. In changing PCOS to PMOS, the global medical community is not merely updating an acronym. It is acknowledging that the condition's complexity deserves to be seen, and that the millions living with it deserve a diagnosis that reflects the truth of what they face.
.svg){kind=logo}
